Our Breakthroughs

Novel approaches to improving safety and efficacy of nucleic acid – based immunotherapies and vaccines

Introduction

Imunon is pioneering technologies and DNA vaccines against infectious diseases and cancers.

The IMUNON team is pioneering technologies that provide the foundation for a range of therapeutics for common, difficult-to-treat forms of cancer as well as technologies for the development of DNA vaccines against infectious diseases and cancers.

We are committed to developing innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Imunon Corporate Fact Sheet

Download the Imunon Corporate Fact Sheet from May 2023

Jeffrey Church

Jeffrey W. Church

Executive Vice President, Chief Financial Officer and Corporate Secretary

Jeffrey W. Church was appointed Senior Vice President and Chief Financial Officer of Imunon in July 2013. The appointment marked Mr. Church’s resumption of the role of Chief Financial Officer, a position he held prior to his promotion to Senior Vice President in July 2011, while also granting him responsibility for corporate investor relations. Mr. Church joined Imunon in July 2010 as Vice President and Chief Financial Officer. He brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining Imunon, Mr. Church held senior financial executive positions with several private and public clinical-stage life science companies, including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm Price Waterhouse. Mr. Church holds a BS degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

Kursheed Anwer

Khursheed Anwer, PhD, MBA

Executive Vice President and Chief Science Officer

Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Science Officer, upon Imunon’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Science Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer has served as an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

Sebastien Hazard, M.D.

Executive vice president & chief Medical officer

Dr. Sebastien Hazard, M.D. was appointed Executive Vice President and Chief Medical Officer of Imunon in December 2023.  Prior to joining Imunon, Dr. Hazard served as Senior Vice President, Head of Clinical Development at Bicycle Therapeutics plc from April 2021 through September 2023.  Prior to joining Bicycle Therapeutics, Dr. Hazard served as Clinical Development Lead at GSK from June 2019 to April 2021.  He also served as Senior Medical Director of Clinical Development from July 2018 to May 2019, and Senior Medical Director of Global Medical Affairs from August 2016 to July 2018 at TESARO, Inc.  Dr. Hazard held various positions within Genentech including Medical Director in Lung Cancer of US Medical Affairs from November 2012 to July 2016.  Earlier in his career Dr. Hazard served as an advisor to the head of the French Drug Agency and to the French Health Minister’s cabinet.  Dr. Hazard holds a Doctorate in Medicine, Internal Medicine and Public Health from Paris VI Pitie Salpetriere an Executive MBA from INSEAD and Master’s degree in epidemiology and statistics applied to clinical research from Paris VI University.